Design Highlights
- The GLP-1 Bridge program offers nationwide coverage for select weight-loss medications from July 1, 2026, to December 31, 2027.
- Beneficiaries will pay a flat monthly copayment of $50 for covered medications, regardless of income.
- Eligibility requires enrollment in a Medicare Part D plan, a minimum age of 18, and a BMI of 27 or higher.
- Covered drugs include Orforglipron, non-injectable semaglutide, and Tirzepatide in KwikPen formulation; injectables are excluded.
- The program serves as a temporary solution pending the delayed BALANCE Model, with uncertain future coverage beyond December 2027.
Medicare is stepping into the weight-loss ring with the launch of the GLP-1 Bridge, but don’t get too excited just yet. This temporary program is set to kick off on July 1, 2026, and run until December 31, 2027. It’s a quick fix before the long-awaited BALANCE Model, which has now been indefinitely delayed. Originally meant to span from January 2027 to December 2031, that plan is now on the back burner. So, what does this mean for those hoping to shed some pounds?
Medicare’s GLP-1 Bridge launches July 2026, offering temporary weight-loss support before the delayed BALANCE Model.
Here’s where it gets interesting. The GLP-1 Bridge offers coverage for select weight-loss medications. If you’re looking for orforglipron (Foundayo), you’re in luck—especially if you prefer it in oral tablet form. Way to go, pills!
The program also covers all versions of semaglutide (Wegovy), as long as you skip the injectable options. And don’t forget about tirzepatide (Zepbound), but remember that only the KwikPen formulation qualifies. Good luck if you were banking on the single-dose pens or vials; they won’t get you anywhere here.
Now, about that price tag. Beneficiaries will face a fixed $50 monthly copayment for a one-month supply. Sounds reasonable, right? Well, not exactly. This copayment isn’t based on your income, and it doesn’t count toward your yearly out-of-pocket limit. That’s right—no deductible either. Just $50 flat, every month. Welcome to the Medicare gym, where you’ll pay to lose weight without any fancy benefits.
Eligibility isn’t a walk in the park either. You need to be at least 18, enrolled in a Medicare Part D plan, and sporting a Body Mass Index (BMI) of 27 or higher. If you’re lucky enough to have a BMI of 35 or more, congratulations! You automatically qualify.
But for those sitting between 27 and 34, you’d better have a comorbid condition like heart disease or prediabetes to get in. Medicaid programs have the option to cover weight-loss drugs, but participation is not guaranteed, which adds another layer of uncertainty to the landscape. Additionally, the Bridge program allows access to GLP-1 drugs outside the traditional Medicare Part D benefit/payment flow, providing a temporary solution for beneficiaries.
Coverage is nationwide, but there’s no guarantee what happens after December 2027. The indefinite delay of the BALANCE Model leaves many wondering: what’s next? Manufacturers participating in the program receive approximately $245 monthly per covered drug, a payment arrangement intended to help manage overall healthcare costs and reduce federal spending. Will the bridge be extended? Will the weight-loss dream fizzle out? Only time will tell. For now, this program acts as a bridge to an uncertain future. So, mark your calendars for 2026, but don’t hold your breath.
